6月9日 - ** 制药商默克MRK.N股价盘前上涨1.7%至80.26美元
** 该公司称其口服药物癸酸恩利替德在两项后期试验中达到了降低坏胆固醇的主要目标 (link)
** 与安慰剂相比，高胆固醇患者的低密度脂蛋白胆固醇明显降低。
** 在已服用他汀类药物（一种常见的降胆固醇药物）的患者中，该药的疗效也优于其他口服非他汀类药物。
** 恩利替德通过抑制一种名为PCSK9的蛋白质起作用，这种蛋白质在调节血液中胆固醇水平方面起著关键作用
** 截至上一交易日收盘，股价累计下跌 20.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.